Drug Trial Radar · NCT06090539
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
460
Planned (sponsor's estimate)
Start
Dec 29, 2023
Primary completion
Oct 28, 2027
Study completion Oct 28, 2028
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Oct 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma.
Conditions
- Relapsed/Refractory Non-Hodgkin Lymphoma
Interventions
BMS-986458Drug
Specified dose on specified days.
RituximabDrug
Specified dose on specified days.
Glofitamab/ObinutuzumabDrug
Specified dose on specified days
MosunetuzumabDrug
Specified dose on specified days
EpcoritamabDrug
Specified dose on specified days
GolcadomideDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: Up to 2 years and 1 month
- Number of participants with serious adverse events (SAEs)Time frame: Up to 2 years and 1 month
- Number of participants with AEs meeting protocol-defined dose-limiting toxicity (DLT) criteriaTime frame: Up to Day 28
- Number of participants with AEs leading to deathTime frame: Up to 2 years and 1 month
- Number of participants with AEs leading to discontinuationTime frame: Up to 2 years and 1 month
- Number of participants with a complete response rate (CRR) according to the Lugano response criteria for Non-Hodgkin Lymphoma by Investigator assessmentTime frame: Up to 2 years and 11 month
Locations
76 sites in 15 countries. Site status is shown where the registry gives one.
Mayo Clinic in Arizona - Phoenix
Phoenix, Arizona · Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
Local Institution - 0068
Jacksonville, Florida · Not yet recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Mayo Clinic in Rochester, Minnesota
Rochester, Minnesota · Recruiting
Local Institution - 0124
Omaha, Nebraska · Not yet recruiting
Local Institution - 0047
Lake Success, New York · Completed
Local Institution - 0037
New York, New York · Not yet recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Local Institution - 0045
Providence, Rhode Island · Not yet recruiting
Local Institution - 0118
Antofagasta, AN, Chile · Not yet recruiting
Local Institution - 0105
Santiago, Metropolitana de Santiago, Chile · Not yet recruiting
Local Institution - 0109
Santiago, Santiago Metropolitan, Chile · Not yet recruiting
Beijing Cancer hospital
Beijing, Beijing Municipality, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Local Institution - 0087
Zhengzhou, Henan, China · Not yet recruiting
Local Institution - 0120
Suzhou, Jiangsu, China · Not yet recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
Local Institution - 0130
Nanchang, Jiangxi, China · Not yet recruiting
Local Institution - 0129
Shenyang, Liaoning, China · Not yet recruiting
Local Institution - 0132
Qingdao, Shandong, China · Not yet recruiting
Local Institution - 0131
Shanghai, Shanghai Municipality, China · Not yet recruiting
Local Institution - 0128
Hangzhou, Zhejiang, China · Not yet recruiting
CHU SAINT ELOI - Departement Hematologie Clinique
Montpellier, France · Recruiting
Hôpital Saint-Louis
Paris, France · Recruiting
Institut Claudius Regaud
Toulouse, France · Recruiting
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
Bordeaux, Aquitaine, France · Recruiting
Local Institution - 0125
Lyon, Nan, France · Not yet recruiting
Hopital Claude Huriez - CHU de Lille
Lille, Nord, France · Recruiting
Gustave Roussy
Villejuif, Paris, France · Recruiting
Henri Mondor Hospital
Créteil, Val-de-Marne, France · Recruiting
Helios Klinikum Berlin-Buch
Berlin, Germany · Recruiting
Universitaetsklinikum Essen
Essen, Germany · Recruiting
Universitätsklinikum Münster - Albert Schweitzer Campus
Münster, North Rhine-Westphalia, Germany · Recruiting
Universitaetsklinikum des Saarlandes
Homburg, Saarland, Germany · Recruiting
Universitätsklinikum Leipzig
Leipzig, Saxony, Germany · Recruiting
Local Institution - 0107
Athens, Greece · Not yet recruiting
Local Institution - 0102
Athens, Greece · Not yet recruiting
Local Institution - 0103
Pátrai, Achaḯa, Greece · Not yet recruiting
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.